Related Experiment Video

Updated: Apr 12, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K

Resistance to Anti-HER2 Therapies in Breast Cancer

Mothaffar F Rimawi1, Carmine De Angelis1, Rachel Schiff1

  • 1From the Lester and Sue Smith Breast Center and Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, TX.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|May 21, 2015
PubMed

Insights

HER2-targeted therapies improve breast cancer outcomes but face resistance. Understanding resistance mechanisms like pathway reactivation is key to developing more effective treatments and optimizing patient results.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • HER2 (Human Epidermal growth factor Receptor 2) is overexpressed in 20-25% of breast cancers.
  • The HER2 signaling pathway is crucial for cancer cell growth and survival.
  • Current anti-HER2 therapies have improved patient outcomes but face challenges.

Purpose of the Study:

  • To explore the therapeutic potential of targeting the HER2 pathway in breast cancer.
  • To investigate the mechanisms underlying resistance to anti-HER2 therapies.
  • To identify strategies for overcoming treatment resistance and improving patient outcomes.

Main Methods:

  • Review of existing literature on HER2 biology and anti-HER2 therapies.
  • Analysis of resistance mechanisms, including pathway redundancy and reactivation.
  • Exploration of combination therapy approaches.

Main Results:

  • Anti-HER2 therapies have shown significant clinical benefits.
  • Treatment resistance is a major obstacle, mediated by pathway reactivation and escape routes.
  • Combination therapies show promise for overcoming resistance.

Conclusions:

  • Targeting the HER2 pathway is a validated strategy in breast cancer treatment.
  • Understanding resistance mechanisms is critical for developing next-generation therapies.
  • Combination strategies are essential for improving long-term patient outcomes in HER2-positive breast cancer.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.2K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K